Hospital
VHS of Arrowhead, INC.
VHS of Arrowhead, INC. was paid $5.21M by Medicaid between Jan 2018 and Dec 2024, across 99 billing codes. Its largest line is 99285, emergency room visit (most serious) — 35% of everything it billed.
33Billing provider infoVHS OF ARROWHEAD, INC.
PHOENIX, AZ 85016
PHOENIX, AZ 85016
33aNPI1255640819assigned 09/30/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.21M
24GClaims156,091
24DCodes billed99
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#50 of 78
Median peer was paid$12.21M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 23,093 | $827K | |
| 2019 | 20,618 | $688K | |
| 2020 | 18,345 | $631K | |
| 2021 | 22,564 | $677K | |
| 2022 | 26,698 | $859K | |
| 2023 | 24,675 | $853K | |
| 2024incomplete | 20,098 | $679K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 35% | 6,066 | 5,595 | $1.83M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 5,025 | 4,721 | $1.09M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 5,597 | 5,214 | $946K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.4% | 509 | 488 | $335K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 4.3% | 559 | 528 | $223K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3.6% | 706 | 302 | $187K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.8% | 96 | 93 | $146K |
| G0378 | Hospital observation service, per hour | 2.1% | 3,116 | 1,605 | $111K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 1,086 | 1,030 | $94K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 891 | 850 | $89K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 51 | 49 | $28K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 204 | 190 | $26K |
87 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 481 | $21K |
| 80053 | Comprehensive metabolic panel | <1% | 9,799 | $19K |
| C1732 | Catheter, electrophysiology, diagnostic/ablation, 3d or vector mapping | <1% | 25 | $16K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,522 | $14K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,843 | $9K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,488 | $5K |
| 96376 | <1% | 309 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 421 | $3K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,966 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,607 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,304 | $1K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 414 | $633.14 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,412 | $631.86 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,326 | $562.62 |
| 93970 | <1% | 12 | $454.36 | |
| 93971 | <1% | 13 | $409.84 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 495 | $375.16 |
| 83880 | <1% | 3,139 | $275.79 | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,862 | $262.64 |
| 86850 | <1% | 675 | $249.77 | |
| C1769 | Guide wire | <1% | 1,288 | $196.50 |
| 84484 | <1% | 7,021 | $158.02 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,429 | $126.69 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 970 | $115.89 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,088 | $95.40 |
| 83735 | <1% | 4,289 | $88.21 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 899 | $79.39 |
| 76937 | <1% | 414 | $72.07 | |
| 80061 | Lipid panel | <1% | 798 | $57.85 |
| 82962 | <1% | 2,954 | $54.08 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,043 | $51.30 |
| 81025 | <1% | 943 | $46.45 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 17 | $41.57 |
| 84703 | <1% | 2,562 | $40.95 | |
| 81001 | <1% | 2,624 | $38.29 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,210 | $32.34 |
| 85379 | <1% | 1,980 | $31.64 | |
| 87088 | <1% | 1,394 | $24.90 | |
| 87400 | <1% | 709 | $23.16 | |
| 83605 | <1% | 756 | $22.91 | |
| 85610 | <1% | 5,282 | $20.69 | |
| 83690 | <1% | 2,257 | $20.55 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 613 | $20.54 |
| 85730 | <1% | 4,337 | $19.44 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,305 | $18.75 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,815 | $16.63 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 640 | $15.98 |
| 84100 | <1% | 419 | $14.32 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,431 | $9.06 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,786 | $8.00 |
| 85027 | <1% | 1,484 | $7.50 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 406 | $6.58 |
| 86901 | <1% | 898 | $2.39 | |
| 86900 | <1% | 898 | $2.38 | |
| 81003 | <1% | 1,685 | $2.32 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 81 | $0.00 |
| 99001 | 0% | 358 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 652 | $0.00 |
| 93017 | 0% | 96 | $0.00 | |
| 73130 | 0% | 24 | $0.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 152 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 28 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 89 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 903 | $0.00 |
| 87186 | 0% | 115 | $0.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 27 | $0.00 |
| 90715 | 0% | 12 | $0.00 | |
| 80076 | 0% | 12 | $0.00 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 17 | $0.00 |
| J3490 | Unclassified drugs | 0% | 517 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 883 | $0.00 |
| 87077 | 0% | 99 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 52 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 307 | $0.00 |
| 82550 | 0% | 388 | $0.00 | |
| 87040 | 0% | 153 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 45 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 74 | $0.00 |
| 87430 | 0% | 26 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 86 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 54 | $0.00 |
| C1730 | Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) | 0% | 29 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 14 | $0.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 86 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 12 | $0.00 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 13 | $0.00 |
| 87081 | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYOUNG, SHALEN (CFO)
Parent organizationVHS OF ARROWHEAD, INC.
| Provider | Location | Paid |
|---|---|---|
| VHS of Arrowhead, INC | Glendale, AZ | $27.72M |
| VHS of Arrowhead, INC. | Surprise, AZ | $4.22M |
| VHS of Arrowhead, INC. | Peoria, AZ | $2.25M |
| VHS of Arrowhead INC | Glendale, AZ | $865.07 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.